A Cheminformatics, Bioorganic, and Medicinal Chemistry Perspective on a Trop-2-Directed Antibody-Drug Conjugate in Urothelial Cancer: A Focused Review

Sacituzumab govitecan-hziy (SG) is a Trop-2-directed antibody-drug conjugate (ADC) built from a humanized anti-Trop-2 immunoglobulin G1 (hRS7), a moderately hydrolyzable CL2A carbonate linker, and the topoisomerase I poison SN-38, the active metabolite of irinotecan. SG received accelerated approval from the U.S. Food and Drug Administration in April 2021 for locally advanced or metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint blockade, on the strength of the single-arm TROPHY-U-01 trial. In October 2024, following the failure of the confirmatory TROPiCS-04 trial to demonstrate an overall-survival benefit, the urothelial indication was voluntarily withdrawn, while indications in breast cancer remain in force. This review sets aside the clinical narrative that has been extensively covered elsewhere and instead reconstructs the ligand-optimization logic of SG from a bioorganic and medicinal chemistry standpoint: the structural biology of the Trop-2 ectodomain and the epitope engaged by hRS7; the structure-activity relationships that govern the camptothecin pharmacophore and dictate why SN-38, rather than camptothecin or irinotecan itself, was selected as payload; the rational design history of the CL2A linker, including its site of attachment on the SN-38 lactone, its deliberately intermediate hydrolytic stability, and the resulting drug-to-antibody ratio of approximately 7.6; and the physicochemical basis of the bystander cytotoxic effect. It then surveys the rapidly growing cheminformatic and computational toolkit -- molecular docking, molecular dynamics, quantitative structure-activity relationship and machine-learning models for drug-to-antibody ratio and payload selection, epitope/paratope prediction, and generative linker design -- that is beginning to formalize what was historically an empirical, iterative medicinal chemistry process. Finally, the review integrates pharmacogenomic (UGT1A1) and structural resistance data (TOP1 E418K, TACSTD2 T256R) to argue that the next generation of Trop-2 ADCs, in urothelial cancer and beyond, will depend less on iterative linker tinkering and more on structure- and data-guided co-optimization of antibody epitope, linker chemistry, and payload pharmacophore.